GERN Share Price Performance
US$0
-1.36 (-100.00%)
Price US$0
Fair ValueUS$3.40
Share Pricen/a
Narrative Update • Aug 06
Geron Corporation Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 57 Fair Values set on narratives written by author
GERN Community Narratives
AN
Fair Value
·Fair Value US$3.4 56.5% undervalued intrinsic discount
Aging Population Trends Will Expand Hematology Market Opportunity
1users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value
·Fair Value US$6 75.3% undervalued intrinsic discount
Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value US$3 50.7% undervalued intrinsic discount
Drug Pricing Controls And Approval Delays Will Curb Viability
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets
Geron is betting that its new cancer-focused treatment can win over doctors faster than many expect, pushing it into wider use and opening up new markets outside the US. But the whole story leans heavily on one expensive drug, so pricing pushback, tougher rules, or stronger rivals could quickly change the outlook.Read more
AN
US$6
75.3% undervalued intrinsic discount
Fair Value
Profit Margin
66.79%
Future PE
9.8x
Price in 2029
US$7.4
Drug Pricing Controls And Approval Delays Will Curb Viability
Geron’s growth story hinges on one cancer drug, but tougher drug-pricing rules, slower approvals, and rising competition could make it harder to keep expanding into new patients and countries. At the same time, strong early uptake and wider insurance coverage could keep momentum going—if the launch continues to deliver.Read more
AN
US$3
50.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.43%
Future PE
24.68x
Price in 2029
US$3.71
Aging Population Trends Will Expand Hematology Market Opportunity
Key Takeaways Expanding patient pool, strong adoption, and premium pricing position Geron for sustained revenue growth and robust margins. Pipeline advances, regulatory progress, and industry partnerships create significant opportunities for multi-geography growth and shareholder value.Read more
AN
US$3.4
56.5% undervalued intrinsic discount
Fair Value
Profit Margin
22.97%
Future PE
24.72x
Price in 2029
US$4.19
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
GERN: Real World Evidence And 2026 Guidance Will Support Bullish Outlook
Fair Value: US$6 75.3% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GERN: Real-World MDS Data Will Support Stronger Future Earnings Power
Fair Value: US$3 50.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GERN: Future Profit Upside Will Be Supported By Conservative Forecast Reset
Fair Value: US$3.4 56.5% undervalued intrinsic discount
24 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Geron Corporation Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.11
- 58.50%
- -33.05%
- 55.0%
About GERN
- Founded
- 1990
- Employees
- 258
- CEO
- WebsiteView website
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
